Technical Analysis for IBIO - iBio, Inc.

Grade Last Price % Change Price Change
D 2.32 5.71% 0.13
IBIO closed down 1.79 percent on Wednesday, November 20, 2024, on 46 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 5.71%
Lower Bollinger Band Walk Weakness 5.71%
Stochastic Reached Oversold Weakness 5.71%
Wide Bands Range Expansion 5.71%
Gapped Up Strength 5.71%
Oversold Stochastic Weakness 5.71%
Boomer Sell Setup Bearish Swing Setup 3.81%
NR7 Range Contraction 3.81%
Lower Bollinger Band Walk Weakness 3.81%
Inside Day Range Contraction 3.81%

   Recent Intraday Alerts

Alert Time
10 DMA Resistance about 3 hours ago
Gap Up Closed about 4 hours ago
Rose Above 10 DMA about 4 hours ago
Gap Up Partially Closed about 4 hours ago
2x Volume Pace about 4 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

iBio, Inc. Description

iBio, Inc., a biotechnology company, engages in the development and commercialization of vaccines and therapeutic proteins through its proprietary iBioLaunch platform technology in the United States. Its product portfolio includes seasonal and H1N1 influenza vaccines for the seasonal influenza virus strains; pandemic avian influenza vaccine for the pathogenic avian influenza viruses; and therapeutic vaccines for human papilloma virus. The company also offers biodefense products, including oral anthrax booster vaccine candidates and candidate plague vaccines. In addition, it provides therapeutic protein product candidates comprising human alpha-galactosidase A for the treatment of Fabry disease; human C-1 esterase inhibitor for the treatment of hereditary angioedema; and human alpha-1 antitrypsin for treatment of disorders caused by a deficiency of alpha-1 antitrypsin. Further, the company offers vaccine enhancements through its iBioModulator platform. It has a license and collaboration agreement with Caliber Biotherapeutics, LLC for the development and production of recombinant plant-based biopharmaceuticals. The company is headquartered in Newark, Delaware.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Disorders Influenza Vaccines Viruses Vaccination Platform Technology Microbiology Angioedema Hereditary Angioedema Biodefense Defense Products Influenza Vaccine Seasonal Influenza Deficiency Fabry Disease Anthrax Avian Influenza Human Papilloma Virus Influenza Viruses Treatment Of Fabry Disease

Is IBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.98
52 Week Low 0.2
Average Volume 145,313
200-Day Moving Average 2.02
50-Day Moving Average 2.42
20-Day Moving Average 2.54
10-Day Moving Average 2.36
Average True Range 0.21
RSI (14) 37.50
ADX 32.21
+DI 14.04
-DI 19.28
Chandelier Exit (Long, 3 ATRs) 2.51
Chandelier Exit (Short, 3 ATRs) 2.71
Upper Bollinger Bands 3.00
Lower Bollinger Band 2.08
Percent B (%b) 0.12
BandWidth 36.14
MACD Line -0.09
MACD Signal Line -0.03
MACD Histogram -0.0641
Fundamentals Value
Market Cap 4.39 Million
Num Shares 2.01 Million
EPS -35.00
Price-to-Earnings (P/E) Ratio -0.06
Price-to-Sales 47.32
Price-to-Book 0.18
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.55
Resistance 3 (R3) 2.58 2.49 2.49
Resistance 2 (R2) 2.49 2.39 2.47 2.47
Resistance 1 (R1) 2.34 2.34 2.29 2.31 2.45
Pivot Point 2.24 2.24 2.22 2.23 2.24
Support 1 (S1) 2.10 2.15 2.05 2.07 1.93
Support 2 (S2) 2.00 2.09 1.99 1.91
Support 3 (S3) 1.85 2.00 1.89
Support 4 (S4) 1.83